-
2023-504741-32-00
4
2022-11-30
Moderately to Severely Active Crohn's Disease
-
2023-504743-13-00
4
2022-11-30
Moderately to Severely Active Ulcerative Colitis
-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2024-514394-22-00
6
2022-10-24
Actinic Keratosis
-
2024-516438-36-00
4
2022-09-13
Patients with very low, low or intermediate risk myelodysplastic syndr
-
2023-503999-24-00
5
2022-06-01
Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
-
2023-506854-19-00
1
2022-05-19
Solid Tumors
-
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
-
2023-505210-18-00
5
2021-12-17
Early stage HER2-positive breast cancer (T stage >= T3, lymph node pos
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2023-506786-63-00
5
2021-09-30
Breast Cancer
-
2024-510812-64-00
5
2021-09-30
Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin recep
-
2024-513091-17-00
5
2021-09-29
Progressive myopia
-
2023-506752-24-00
5
2021-08-05
Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
-
2023-506270-13-00
4
2021-07-27
Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2023-504997-39-00
5
2021-06-14
Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
-
2023-504161-22-00
4
2021-06-04
Active Discoid and/or Subacute Cutaneous Lupus Erythematosus
(DLE/SCLE
-
2023-505249-24-00
5
2021-05-27
HER2-positive metastatic breast cancer
-
2024-511753-22-00
5
2021-05-26
Primary Biliary Cholangitis
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2022-501645-70-00
5
2020-11-25
Crohns Disease
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2022-502084-38-00
5
2020-10-16
Cancer